Tenaya Therapeutics Inc

Tenaya Therapeutics Inc maintains a strong liquidity position, with a current ratio of 6.28 and $58.13 million in cash and equivalents, indicating a robust short-term financial buffer. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage. The price-to-book ratio of 1.51 and price-to-tangible-book ratio of 1.51 indicate that the company's market value is slightly above its book value, but not significantly so. The company is currently unprofitable, with a net loss of $29.43 million and an operating loss of $30.82 million in the latest reporting period. Return on equity (ROE) and return on assets (ROA) are negative at -21.96% and -18.04%, respectively, indicating poor capital efficiency and asset utilization. The EV/EBITDA ratio is negative at -4.696, reflecting the company's lack of earnings and the challenges it faces in generating positive cash flows. Tenaya Therapeutics Inc operates as a single business segment, with no disclosed geographic revenue breakdown. The company's operations are concentrated in the United States, and it does not report revenue by region or product line. This lack of diversification increases exposure to regulatory, market, and operational risks in the U.S. biotechnology sector. The company's growth trajectory is uncertain, with no disclosed revenue in the latest period and a negative operating cash flow of $52.28 million. Free cash flow is also negative at $27.38 million, indicating that the company is not generating sufficient cash to fund operations or growth without external financing. Analysts have provided a wide range of price targets, from $2.00 to $40.00, with a mean of $9.00 and a median of $3.00, reflecting significant uncertainty about the company's future performance. Risk factors include the company's reliance on external financing to fund operations, as well as the inherent risks associated with drug development, including clinical trial failures and regulatory delays. The risk assessment indicates low liquidity and dilution risk, but the company's capital structure is vulnerable to changes in market conditions or financing needs. No immediate filing-based liquidity or dilution flags were detected, but the company's negative cash flows and lack of earnings suggest ongoing financial pressure. Recent events include the continued development of its lead candidate, TNY-301, for the treatment of rare diseases, with no recent major clinical or regulatory updates disclosed in the latest financial filings. The company has not issued any new equity or debt in the latest reporting period, and there are no disclosed plans for future financing activities.